title: Severe periorbital edema secondary to STI571 (Gleevec).
abstract: STI571 (imatinib mesylate; Gleevec) is a selective inhibitor of the bcr-abl, c-kit, and platelet-derived growth factor receptor tyrosine kinases. Mild periorbital edema has been noted as a common side effect in Phase I and II trials of this drug for the treatment of patients with chronic myelogenous leukemia and gastrointestinal stromal tumors. The authors report the case of male patient age 63 years who developed severe periorbital edema after treatment with STI571 for chronic myelogenous leukemia. His edema was severe enough to cause visual obstruction due to lower eyelid festoons that ultimately required surgical debulking. Histopathologic analysis of specimens of the excised upper and lower eyelid tissue revealed dermal dendrocytes that expressed the platelet-derived growth factor receptor and c-kit tyrosine kinases, suggesting a possible role for dermal dendrocytes in the development of this toxic effect.
authors.affiliation: Ophthalmology Section, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. besmaeli@mdanderson.org
authors.forename: Bita
authors.initials: B
authors.lastname: Esmaeli
authors.forename: Victor G
authors.initials: VG
authors.lastname: Prieto
authors.forename: Charles E
authors.initials: CE
authors.lastname: Butler
authors.forename: Stella K
authors.initials: SK
authors.lastname: Kim
authors.forename: M Amir
authors.initials: MA
authors.lastname: Ahmadi
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Moshe
authors.initials: M
authors.lastname: Talpaz
mesh_terms: D001549:Benzamides; D004487:Edema / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009915:Orbit / Q000033:anatomy & histology; D009916:Orbital Diseases / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases